Pharmacokinetics and pharmacodynamics of antifungal drugs in children-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of antifungal drugs in children

Published:2018-02 Issue:1 Volume:3 Page:39-56
ISSN:2053-0846
Container-title:International Journal of Pharmacokinetics
language:en
Short-container-title:International Journal of Pharmacokinetics

Author:

Padoin Christophe¹,Lanternier Fanny²³,Lortholary Olivier²³,Jullien Vincent⁴⁵

Affiliation:

1. Service de Pharmacie, Hôpital Avicenne, Bobigny, France

2. Service de Maladies Infectieuses et Tropicales, Hôpital Necker – Enfants Malades, Paris, France

3. CNR Mycologie et Antifongiques, CNRS URA3012, Institut Pasteur, Paris, France

4. Service de Pharmacologie, Hôpital Européen Georges Pompidou, Paris, France

5. INSERM U1129, Paris, France

Abstract

Providing an adequate exposure to antifungal drugs is a crucial aspect of the treatment of invasive fungal infections. Consequently, the age-related pharmacokinetic changes during childhood must be taken into account to determine the dose to be administered in children. The present article proposes an updated review of the pediatric pharmacology of the main antifungal drugs currently used (amphotericin B, flucytosine, triazole compounds and echinocandins). Last, the relevance for children of the current guidelines for the therapeutic drug monitoring of antifungal drugs is discussed.

Publisher

Future Science Ltd

Link

http://www.future-science.com/doi/pdf/10.4155/ipk-2017-0016

Reference130 articles.

1. Attributable Mortality of Nosocomial Candidemia, Revisited

2. Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients

3. Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

4. Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children

5. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections